United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of unique products to address the unmet medical needs of patients with chronic ...

United Therapeutics’ xenokidney ... today’s milestone reinforces that we are on track to fulfill our ultimate mission to create an unlimited supply of transplantable organs and organ ...

Silver Spring’s United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to be transplanted into humans. It's as significant for the ...

Two US biotech companies say the Food and Drug Administration has cleared them to conduct clinical trials of their ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application (IND ...

United Therapeutics said the FDA has cleared it to begin the first clinical trial testing whether organs from gene-edited ...

UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...

United Therapeutics UTHR has outperformed the market over the past 20 years by 6.47% on an annualized basis producing an average annual return of 14.94%. Currently, United Therapeutics has a ...